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Summary
 
The requirement for major histocompatibility complex class II (MHC II) to initiate immune
renal injury was studied in a murine model of CD4
 
1
 
 T cell–dependent crescentic glomerulo-
 
nephritis (GN). C57BL/6 (MHC II
 
1
 
/
 
1
 
)
 
 mice developed crescentic GN with glomerular CD4
 
1
 
T cell infiltration and renal injury, in response to a nephritogenic antigen (sheep globulin)
planted on their glomerular basement membrane. MHC II–deficient C57BL/6 mice (MHC
II
 
2
 
/
 
2
 
)
 
 did not develop crescentic GN, CD4
 
1
 
 T cell infiltration, or injury, indicating that this
form of immune glomerular injury is MHC II dependent. The requirement for MHC II ex-
pression by intrinsic renal cells was studied in chimeric mice, which expressed MHC II on
bone marrow–derived cells and in the thymus, but not in the kidneys. These chimeric mice
had normal T and B cell populations and MHC II expression in their spleens and lymph nodes
and developed an immune response to systemically and cutaneously administered sheep globu-
lin. However, they did not develop crescentic GN, CD4
 
1
 
 T cell infiltration, or renal injury in
response to the sheep globulin planted in their glomeruli. These studies demonstrate that inter-
action of CD4
 
1
 
 T cells with intrinsic renal cells expressing MHC II is required for develop-
ment of cell-mediated immune renal injury.
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T
 
cell responses are normally dependent on recognition
of antigen bound to MHC molecules on the surface of
APCs. MHC class I molecules are predominantly associated
with CD8
 
1
 
 cytotoxic T cell responses. MHC class II (MHC
II) molecules present antigens to CD4
 
1
 
 T cells, which stim-
ulate antibody production and isotype switching and act as
effector cells for local cell-mediated immune responses.
“Professional” APCs are bone marrow–derived cells that
present antigen to naive T cells in secondary lymphoid tis-
sues. After activation, T cells enter nonlymphoid tissues,
where they can recognize antigen and initiate local im-
mune responses. It is well accepted that MHC II is required
during activation of naive CD4
 
1
 
 T cells in secondary lym-
phoid tissues. However, the functional contribution of
MHC II on resident cells to the effector phase of cell-
mediated immune injury targeted at specific tissues in vivo
is unknown. MHC II expression can be stimulated on cells
in many organs, including mesangial cells (1, 2) and proxi-
mal tubular cells in the kidney (3, 4). Thyroid epithelial
cells expressing “aberrant” MHC II can present viral anti-
gens to cloned human T cells in vitro (5).
Glomerular antibody deposition and/or accumulation of T
cells is observed in the majority of cases of human glomerulo-
nephritis (GN). These immune effectors localize in response
to endogenous glomerular antigens or antigens deposited in
glomeruli as components of immune complexes or because of
their size or charge characteristics. In the most severe forms of
human GN, glomerular injury is manifested by a “prolifera-
tive” histological pattern, accumulation of T cells and mac-
rophages, proliferation of intrinsic glomerular cells, accumula-
tion of cells and fibrin in Bowman’s space (“crescents”), and
rapid deterioration of renal function. Studies of crescentic
forms of human (6, 7) and experimental GN (8, 9) suggest an
important effector role for CD4
 
1
 
 T cells. Glomerular deposi-
tion of Ig is often sparse or absent in crescentic human GN
(7), and in an experimental model, crescent formation has
been demonstrated to be antibody independent (10). How-
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ever, the role of glomerular MHC II expression in the local
immune effector response is unknown.
MHC II-deficient mice have near complete elimination
of mature CD4
 
1
 
 T cells in peripheral lymphoid organs and
do not develop MHC II–dependent immune reactions
(11). B cell responses to T cell–independent but not T cell–
dependent antigens are preserved. These mice were used to
determine the requirement for MHC II for development of
crescentic GN in a CD4
 
1
 
 T cell–dependent murine model,
initiated by a nephritogenic antigen planted on the glomer-
ular basement membrane (GBM). The contribution of
MHC II on intrinsic renal cells was studied in chimeric
mice, which had functional CD4
 
1
 
 T cells but did not ex-
press MHC II on intrinsic renal cells.
 
Materials and Methods
 
Mice.
 
MHC II–deficient (MHCII
 
2
 
/
 
2
 
) mice, generated by tar-
geted disruption of the MHCII Aa gene in C57BL/6 mice as de-
scribed previously (11), were housed under specific pathogen–
free conditions.
 
Generation of MHC II Chimeric Mice.
 
Chimeric mice (B6
 
®
 
MHC
 
2
 
/
 
2
 
) expressing MHC II on bone marrow–derived cells but
not in other organs were generated using previously described bone
marrow and thymus transplantation protocols (12). MHCII
 
2
 
/
 
2
 
 mice
were thymectomized at 4 wk of age, irradiated with 700 rad at 7
wk of age, and transplanted with T cell–depleted bone marrow
from B6 (C57BL/6) mice. After an additional 4 wk, mice were
engrafted under the kidney capsule with a thymus from an irradi-
ated (900 rad) newborn wild-type (WT) mouse. B6 mice were
subjected to an identical transplantation process to generate con-
trol (B6
 
®
 
B6) chimeras.
 
Assessment of Lymphocyte Populations in Chimeric Mice.
 
Lympho-
cyte subsets in pooled spleen and LN cell suspensions were as-
sessed by flow cytometry using the following mAbs: FITC-con-
jugated anti-B220, PE-conjugated anti-CD4, PE-conjugated
anti-CD8, and FITC-conjugated anti-CD3 (PharMingen, San
Diego, CA) as described previously (10). MHC II expression on
B cells was assessed using FITC-conjugated anti-MHCII (Phar-
Mingen).
 
Induction of anti-GBM GN and Assessment of Renal Injury.
 
Crescentic GN was initiated in mice by a single intravenous in-
jection of 10 mg of sheep anti-GBM globulin, as described previ-
ously (13). Renal injury and other parameters were assessed 21 d
later. Histological assessment was performed on 2-
 
m
 
m periodic
acid-Schiff–stained kidney sections. Crescent formation was as-
sessed in a minimum of 30 glomeruli, in a blinded protocol, as
described previously (13, 14). Proteinuria was determined by the
Bradford method over the final 24 h of each experiment as de-
scribed (15). Creatinine clearance was calculated from the serum
and urine creatinine concentrations, which were measured by the
alkaline picric acid method using an autoanalyzer (Cobas Bio; L.
Hoffman-La Roche Ltd., Basel, Switzerland).
 
Assessment of Humoral and Cellular Immune Effectors in Glomeruli.
 
Glomerular deposition of mouse IgG was assessed on cryostat-cut
kidney tissue sections (4 
 
m
 
m) stained with serial dilutions of
FITC-conjugated sheep anti–mouse IgG (Silenus, Hawthorn,
Victoria, Australia) to determine the end point titer for detection
in each animal. Glomerular T cell and macrophage accumulation
was assessed on cryostat-cut spleen and kidney tissue sections (6
 
m
 
m) stained to demonstrate macrophages and T cells using the
two-layer peroxidase technique as described (10). The primary
antibodies were H129 (monoclonal anti–mouse CD4; American
Type Culture Collection, Rockville, MD) and M1/70 (mono-
clonal anti–mouse Mac-1; American Type Culture Collection).
Sections of spleen provided a positive control, and protein G–puri-
fied rat Ig was substituted for primary mAb to provide a negative
control. A minimum of 20 equatorially sectioned glomeruli were
assessed per animal, and the results were expressed as cells per
glomerular cross section (c/gcs).
 
Assessment of the Systemic Immune Response to Sheep Globulin.
 
Cutaneous delayed-type hypersensitivity (DTH) to the sheep
globulin was assessed by intradermal challenge with 0.5 mg in 20
 
m
 
l of PBS into the hind foot of mice, 20 d after the systemic ad-
ministration of sheep anti–mouse GBM globulin, as described
previously (14). Ovalbumin (Sigma-Aldrich Pty. Ltd., Castle Hill,
NSW, Australia) injected into the opposite foot pad was used as a
control. Circulating titers of mouse anti–sheep globulin antibody
were measured by ELISA as described previously (10, 14). Opti-
cal densities (405 nm) were converted to micrograms per millili-
ter of antibody by reference to a standard curve generated with
known concentrations of bound mouse IgG. Serum from six
nonimmunized mice was used as normal control. Isotypes of
anti–sheep globulin antibody were also measured by ELISA at a
single dilution of mouse serum optimized for each isotype (1 in
20 for IgG2a, 1 in 40 for IgG1, IgG2b, and IgG3, and 1 in 80 for
IgM) using horseradish peroxidase–conjugated goat anti–mouse
IgG1, IgG2a, IgG2b, IgG3, and IgM (Southern Biotechnology
Associates, Inc., Birmingham, AL) at a dilution of 1:4,000.
 
Experimental Design and Statistical Analysis.
 
The development
of GN 21 d after anti-GBM globulin administration was studied
in the following groups of mice: B6 (C57BL/6) mice (
 
n
 
 
 
5
 
 7),
MHCII
 
2
 
/
 
2
 
 mice (
 
n
 
 
 
5
 
 8), B6
 
®
 
MHCII
 
2
 
/
 
2
 
 chimeric mice
(MHCII
 
1
 
/
 
1
 
 thymus and bone marrow in MHC
 
2
 
/
 
2
 
 mice; 
 
n
 
 
 
5
 
 8),
and B6
 
®
 
B6 (control) chimeric mice (MHCII
 
1
 
/
 
1
 
 thymus and
bone marrow in MHCII
 
1
 
/
 
1
 
 mice; 
 
n
 
 
 
5
 
 8). In addition, measure-
ments of baseline renal function were performed on the following
separate groups of nonnephritic mice: B6 (C57BL/6) mice (
 
n
 
 
 
5
 
8), MHCII
 
2
 
/
 
2
 
 mice (
 
n
 
 
 
5
 
 7), and B6
 
®
 
B6 chimeric mice (
 
n
 
 
 
5
 
 8).
Results are presented as mean 
 
6
 
 SEM. Statistical analysis was per-
formed by one-way analysis of variance, with post hoc analysis
using Fisher’s protected least significant differences (PLSD) test.
 
Results
 
Development of Crescentic GN is MHC II Dependent.
 
B6
(MHCII
 
1
 
/
 
1
 
) mice developed severe proliferative GN (Fig.
1 
 
A
 
) with crescents in 56.5 
 
6
 
 5.2% of glomeruli. This re-
sulted in significant proteinuria (15.5 
 
6
 
 1.5 mg/24 h; base-
 
Table 1.
 
Serum Levels of Specific Mouse anti–sheep
Globulin Antibody
 
Group Specific serum antibody
 
m
 
g/ml
 
B6 with GN 125 
 
6
 
 29
MHCII
 
2
 
/
 
2
 
 with GN Undetectable
B6
 
®
 
B6 with GN 121 
 
6
 
 14
B6
 
®
 
MHCII
 
2
 
/
 
2
 
 
 
with GN 158 
 
6
 
 34 
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line 2.4 
 
6
 
 0.3 mg/24 h,
 
 P 
 
,
 
0.0001) and impairment of re-
nal function (creatinine clearance, 66.4 
 
6
 
 9.0 
 
m
 
l/min;
baseline 112.4 
 
6
 
 7.7 
 
m
 
l/min,
 
 P 
 
5
 
 0.0397) (Fig. 2), and
was associated with evidence of systemic and local immune
responses to sheep globulin. Mouse anti–sheep globulin an-
tibody was present in the serum (125 
 
6
 
 29 
 
m
 
g/ml specific
mouse anti–sheep globulin antibody), and prominent linear
deposition of mouse Ig was observed in glomeruli. Accu-
mulation of CD4
 
1
 
 T cells (1.42 
 
6
 
 0.37 c/gcs; normal 0.21 
 
6
 
0.4 c/gcs) and macrophages (2.21 
 
6
 
 0.17 c/gcs; normal
0.37 
 
6
 
 0.09 c/gcs) in glomeruli was also observed. In con-
trast, MHCII
 
2
 
/
 
2
 
 mice did not develop proliferative GN
(Fig. 1 
 
B
 
) or crescent formation (0% of glomeruli). Pro-
teinuria was not increased (2.7 
 
6 0.3 mg/24 h; baseline 2.2 6
0.3 mg/24 h), and renal function was preserved (creatinine
clearance 125.7 6 9.1 ml/min; baseline 148.6 6 22.9 ml/
min) (Fig. 2). Specific anti–sheep globulin antibody in the
serum was undetectable, as was glomerular deposition of
mouse Ig. Glomerular CD41 T cells (0.08 6 0.01 c/cgs)
and macrophages (0.40 6 0.12 c/gcs) were not increased
compared with the numbers observed in normal (nonne-
phritic) glomeruli.
B6®MHCII2/2 Chimeric Mice Express MHC II in Spleen
and LN Cells and Have Normal Lymphocyte Subsets. Lympho-
cyte subset populations and immune competence of chi-
meric mice were assessed 21 d after administration of anti-
GBM globulin. Thymic grafts contained similar numbers of
cells in both control (B6®B6) and B6®MHCII2/2 chimeras
(B6®B6, 3.22 6 0.48 3 107 cells per graft; B6®MHCII2/2
mice, 2.06 6 0.14 3 107 cells per graft). Pooled splenic and
LN lymphocyte populations in B6®MHCII2/2 mice
(CD41, 24.5 6 5.0%; CD81, 12.1 6 4.5%; B2201, 45.4 6
8.9% of CD31) and B6®B6 mice (CD41, 22.1 6 3.5%;
CD81, 10.0 6 1.9%; B2201, 56.2 6 7.0% of CD31) were
similar to those in a normal mouse (CD41, 18.6%; CD81,
11.9%; B2201, 44% of CD31). Their splenic and LN B
cells showed similar levels of MHC II expression (Fig. 3).
B6®MHCII2/2 Chimeric Mice Develop a Systemic Immune
Response to Sheep Globulin. The systemic immune response
to sheep globulin was similar in chimeric B6®MHCII2/2
Figure 1. Histological appearance of the glomerular lesions, 21 d after anti-GBM globulin administration, in C57BL/6 (A), MHCII2/2 (B), B6®B6
(control) chimeric (C), and B6®MHCII2/2 chimeric mice (D). Periodic acid-Schiff stain, original magnification 3250.600 MHC II on Intrinsic Renal Cells Directs Immune Glomerular Injury
mice and B6®B6 controls. Both groups had similar
amounts of specific mouse anti–sheep globulin antibody in
their serum (B6®MHCII2/2 with GN, 158 6 43 mg/ml;
B6®B6 controls with GN, 121 6 29 mg/ml) and similar
antigen-specific Ig isotype profiles (data not shown). Anti-
gen-specific foot pad swelling after intradermal challenge
(B6®B6, 0.35 6 0.03 mm; B6®MHCII2/2, 0.27 6 0.09
mm; WT, 0.29 6 0.05 mm) indicated that cutaneous
DTH to sheep globulin was equivalent. These data demon-
strate that the CD41 compartment in B6®MHCII2/2
mice is functional.
Absence of MHC II Expression by Intrinsic Glomerular Cells Pre-
vents Development of Crescentic GN. Control chimeric mice
(B6®B6) developed GN similar to B6 (nontransplanted)
mice, with severe proliferative changes (Fig. 1 C) and cres-
cents in 43.2 6 8.9% of glomeruli. Deposition of mouse IgG
(data not shown), accumulation of CD41 T cells (1.17 6
0.11 c/gcs) and macrophages (2.24 6 0.14 c/cgs), and re-
nal injury indicated by significant proteinuria (4.9 6 1.9
mg/24 h; baseline 0.53 6 0.10 mg/24 h, P ,0.0001) and
reduced creatinine clearance (88.1 6 25.5 ml/min) were
similar to B6 mice with GN. In contrast, chimeric mice
(B6®MHCII2/2) showed no proliferative changes in
glomeruli (Fig. 1 D) and did not develop crescents (0% of
glomeruli). Glomerular deposition of mouse Ig was unaf-
fected; however, accumulation of CD41 T cells (0.46 6
0.08 c/gcs) and macrophages (0.74 6 0.21 c/gcs) was
markedly reduced. These mice did not develop significant
proteinuria (2.7 6 0.3 mg/24 h, P 5 0.468 compared with
the baseline in B6®B6 mice) or impairment of renal func-
tion (creatinine clearance 122.3 6 30.6 ml/min) (Fig. 4).
Discussion
Previous studies have demonstrated that crescentic GN
in C57BL/6 mice is T cell dependent in the effector phase
(14). Injury requires CD41 T cell–directed macrophage ac-
cumulation (13, 14) and does not require an autologous an-
tibody response to the planted nephritogenic antigen (10).
T cells and macrophages are evident in glomeruli within 7 d
of administration of anti-GBM globulin, and their numbers
progressively increase to day 21, as does renal injury (13).
Using this model, our current studies demonstrate the re-
quirement for MHC II expression for the development of
this cell-mediated immune renal injury. MHC II–deficient
mice failed to develop a systemic immune response to the
nephritogenic antigen (with no detectable circulating anti-
gen-specific antibody or DTH when challenged cutane-
ously) and did not develop a local immune response when
this antigen was planted in their glomeruli.
Studies of murine lupus have demonstrated that autoan-
tibodies and renal disease do not develop in MHC II–defi-
cient MRL/lpr mice, despite the development of lymphad-
enopathy and massive expansion of CD42CD82 (double
negative) T cells (16). Renal injury in MRL/lpr mice is as-
sociated with glomerular deposition of immune complexes
and is B cell dependent (17). Together with our current
studies, they provide evidence for a pivotal role for MHC
II in the development of both cell-mediated (CD41-
dependent) and antibody-dependent immune glomerular
injury.
Chimeric mice were generated to identify the MHC II–
expressing cell type recognized by CD41 T cells in the
glomerulus. They lacked MHC II expression on non-bone
marrow–derived intrinsic renal cells but had normal levels
of MHC II expression on bone marrow–derived cells.
Analysis of spleen and LNs confirmed normal lymphocyte
subsets and normal CD41 to CD81 T cell ratios in trans-
planted chimeric mice. Their systemic immune response to
the nephritogenic antigen was intact. The circulating anti-
gen-specific antibody levels and isotype profiles and the de-
velopment of a local DTH reaction after cutaneous chal-
lenge demonstrated that these mice develop competent
CD41 T cell–dependent immune responses after antigen
presentation by bone marrow–derived professional APCs.
Figure 2. Proteinuria and cre-
atinine clearance in normal (light
gray bars) C57BL/6 (B6) and
MHCII2/2 mice, and 21 d after
anti-GBM globulin administra-
tion (dark gray bars). *Signifi-
cantly different from baseline
values. **Significantly different
from WT mice with GN.
Figure 3. Flow cytometry profiles demonstrating expression of MHC
II on splenic and LN cells from normal C57BL/6 and MHCII2/2 mice,
and B6®MHCII2/2 and B6®B6 mice with GN. Vertical dashed lines,
Upper limit for background fluorescence.
Figure 4. Proteinuria and cre-
atinine clearance in B6®B6
(control) and B6®MHCII2/2
chimeric mice, 21 d after anti-
GBM globulin. *Significantly
different from baseline values.
**Significantly different from B6
mice with GN.601 Li et al. Brief Definitive Report
However, chimeric mice lacking MHC II in their kidneys
failed to develop local (CD41 T cell–dependent) immune
injury when the same antigen was planted in their glomeruli.
This demonstrates that MHC II expression by intrinsic renal
cells is required for antigen-specific CD41 T cell recruitment
and initiation of cell-mediated immune renal injury.
Various renal cell types, including mesangial cells (1, 2)
and tubular epithelial cells (3, 4), can express MHC II.
CD41 T cell lines and hybridomas can recognize antigen
processed and presented by proximal tubular cells (4) and
thyroid epithelial cells (5) in vitro, although less efficiently
than with antigen processed by bone marrow–derived
APCs. Endothelial cells also have the capacity to express
MHC II (18, 19). Our current studies were not able to de-
fine which of these cell types are recognized by CD41 T
cells in the kidney. Despite the existence of MHC II1 (Ia1)
cells in rat glomeruli (20) and MHC II1 dendritic cells in
rodent (21, 22) and human kidneys (23), these bone mar-
row–derived cells are not sufficient to target the immune
response to the kidney and initiate crescentic GN.
Upregulation or novel expression of MHC II by renal
cells has been demonstrated in many conditions, including
allograft rejection (24), GVHD (25), lupus nephritis (26),
and IgA disease (27). Tubular epithelial cells can present
antigen to T cell clones derived from kidneys of MRL/lpr
mice, but their ability to perform this function in vivo has
not been clearly demonstrated (28). MHCII2/2 kidneys
transplanted into MRL/lpr mice still develop GN and in-
terstitial inflammatory cell infiltrates (29). This indicates
that expression of MHC II by intrinsic renal cells is not re-
quired for development of this antibody-dependent form
of GN, in which the immune effector response is targeted
to the glomerulus (and other vascular beds) because of local
immune complex deposition. In contrast, this study dem-
onstrates that GN, initiated by a planted nephritogenic an-
tigen and directed by CD41 T cells, requires MHC II ex-
pression by intrinsic renal cells. These results provide the
first demonstration of the functional importance of local
MHC II expression by intrinsic renal cells for targeting an
immune injury to the glomerulus.
Because a systemic immune response to the nephritoge-
nic antigen was observed, it is likely that naive CD41 T
cells are activated in secondary lymphoid organs by profes-
sional APCs after intravenous antigen challenge. It is un-
likely that intrinsic renal cells participate in this initial prim-
ing, although we cannot exclude such a role. However,
any contribution of this to the subsequent immune re-
sponse would seem negligible, as chimeric mice without
MHC II in their kidneys develop a systemic immune re-
sponse to the nephritogenic antigen that is indistinguishable
from that in normal mice. Expression of MHC II by intrin-
sic renal cells would appear to be functionally important in
the effector phase of this disease, but was not necessary for
initiation of the primary immune response.
In conclusion, these studies provide evidence for MHC
II–dependent CD41 T cell–directed injury in crescentic
GN. In addition, they demonstrate that in the effector
phase of this disease, MHC II expression by intrinsic renal
cells is required to direct the CD41 T cell effector response
in the glomerulus, and that MHC II on bone marrow–
derived cells alone is not sufficient. This provides the first
demonstration of a requirement for MHC II expression by
nonprofessional APCs for development of a T cell–depen-
dent injury. The approach of transplanting MHC-intact
bone marrow and thymus into MHC-deficient mice may
be used to explore the role of local MHC II expression in a
variety of CD41 T cell–dependent organ-specific immune
diseases.
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